TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33596357

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (40 mg of relugolix, 1 mg of estradiol, and 0.5 mg of norethindrone acetate)
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Relugolix monotherapy
Number of subjects: 770
Study: 32537887

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 47
Study: 34053111

Group type: EXPERIMENTAL
Intervention: Cracked corn (CC: 74% NSC & 9% CP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ration balancer with low protein (RB-LP: 15% NSC & 17% CP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ration balancer with high protein (RB-HP: 14% NSC & 37% CP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low NSC pellet (L-NSC: 6% NSC & 12% CP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Steam-flaked corn (SF: 73% NSC & 10% CP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Oat groats (OG: 64% NSC & 14% CP)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 50:50 mixture of RB-LP:RB-HP (MIX-P)
Number of subjects: 18
Study: 34548555

Group type: EXPERIMENTAL
Intervention: Costoclavicular block (group C) with 25 mL of local anesthetics (1:1 mixture of 1% lidocaine and 0.75% ropivacaine)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supraclavicular block (group S) with 25 mL of local anesthetics (1:1 mixture of 1% lidocaine and 0.75% ropivacaine)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Costoclavicular block (group C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Supraclavicular block (group S)
Number of subjects: 80
Study: 36521349

Group type: EXPERIMENTAL
Intervention: 0.1 % w/w Liposomal Amphotericin‐B gel
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 10 % w/w Povidone‐Iodine
Number of subjects: 45

Group type: COMPARATOR
Intervention: Saline nasal douching
Number of subjects: 45
Study: 34144995

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering therapy
Number of subjects: 863
Study: 33002071

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure reduction (SBP target < 120 mmHg)
Number of subjects: 4292

Group type: COMPARATOR
Intervention: Standard treatment (SBP target < 140 mmHg)
Number of subjects: 4292
Study: 35785539

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 33513546

Group type: EXPERIMENTAL
Intervention: Breastfeeding
Number of subjects: 39

Group type: COMPARATOR
Intervention: Oral sucrose (0.24 mL of 24% oral sucrose plus non-nutritive sucking)
Number of subjects: 39
Study: 32253895

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (AC)
Number of subjects: 24
Study: 35253727

Group type: EXPERIMENTAL
Intervention: Casein phosphopeptide amorphous calcium fluoride phosphate (CPP-ACFP)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Calcium glycerophosphate (CaGP)
Number of subjects: 22
Study: 32077909

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL) implantation at the time of cataract surgery
Number of subjects: 114

Group type: COMPARATOR
Intervention: Aphakia (contact lens correction)
Number of subjects: 114
Study: 35247908

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (KEYNOTE-052)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks (KEYNOTE-045)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel/docetaxel/vinflunine) (KEYNOTE-045)
Number of subjects: 0
Study: 32216011

Group type: EXPERIMENTAL
Intervention: Vericiguat 10.0 mg
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Vericiguat 5.0 mg
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335
Study: 35222898

Group type: EXPERIMENTAL
Intervention: Sacubitril valsartan
Number of subjects: 60

Group type: COMPARATOR
Intervention: Valsartan
Number of subjects: 60
Study: 33239106

Group type: EXPERIMENTAL
Intervention: Intervention package including simple, accurate diagnostic tests, clinical algorithms, and training and communication.
Number of subjects: 21876

Group type: COMPARATOR
Intervention: Current practice (control group).
Number of subjects: 21876
Study: 35818134

Group type: EXPERIMENTAL
Intervention: TAC/Collagen gel
Number of subjects: 20
Study: 34800399

Group type: EXPERIMENTAL
Intervention: avalglucosidase alfa
Number of subjects: 100

Group type: COMPARATOR
Intervention: alglucosidase alfa
Number of subjects: 100
Study: 34428980

Group type: EXPERIMENTAL
Intervention: BGF 320/18/9.6 µg
Number of subjects: 3088

Group type: EXPERIMENTAL
Intervention: BGF 160/18/9.6 µg
Number of subjects: 3088

Group type: COMPARATOR
Intervention: GFF 18/9.6 µg
Number of subjects: 3088

Group type: COMPARATOR
Intervention: BFF 320/9.6 µg
Number of subjects: 3088
Study: 32444980

Group type: EXPERIMENTAL
Intervention: FSRS plus BEV-based chemotherapy
Number of subjects: 35

Group type: COMPARATOR
Intervention: BEV-based chemotherapy alone
Number of subjects: 35
Study: 32781457

Group type: COMPARATOR
Intervention: 2.5‐mg hypobaric bupivacaine alone
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2.5‐mg hypobaric bupivacaine and 10‐μg fentanyl
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 2.5‐mg hypobaric bupivacaine and 0.5‐mg morphine
Number of subjects: 90
Study: 34087752

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Mindfulness-based intervention (BMT)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Active comparison group (QoL)
Number of subjects: 106
Study: 35537794

Group type: EXPERIMENTAL
Intervention: WeChat-based mini-app intervention
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 70
Study: 33709448

Group type: EXPERIMENTAL
Intervention: 1 sentinel node removed
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: 2 sentinel nodes removed
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: ≥3 sentinel nodes removed
Number of subjects: 190
Study: 35184123

Group type: EXPERIMENTAL
Intervention: Pachymetry mapping 1 day after DMEK
Number of subjects: 65
Study: 33741218

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid (HA) combined with triamcinolone
Number of subjects: 28

Group type: COMPARATOR
Intervention: Triamcinolone alone
Number of subjects: 28
Study: 34505171

Group type: EXPERIMENTAL
Intervention: Continence Pessary (CP)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Disposable Intravaginal Continence Device (DICD)
Number of subjects: 50
Study: 32048900

Group type: COMPARATOR
Intervention: Tacrolimus 0.1% ointment
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tacrolimus 0.1% ointment plus PSD
Number of subjects: 49
Study: 32994242

Group type: EXPERIMENTAL
Intervention: Metformin (various dosages)
Number of subjects: 2500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2500
Study: 35209870

Group type: EXPERIMENTAL
Intervention: Health-related physical fitness T-score (HPFT)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: One-leg balance
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20 m shuttle run test
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Health-related physical fitness T-score (HPFT) (highest tertile)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: One-leg balance (highest tertile)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 20 m shuttle run test (highest tertile)
Number of subjects: 120
Study: 34207870

Group type: COMPARATOR
Intervention: Concomitant therapy (esomeprazole 40 mg, amoxicillin 1 gr, metronidazole 500 mg, clarithromycin 500 mg, twice daily for 14 days)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Tailored therapy based on antimicrobial susceptibility testing
Number of subjects: 80
Study: 33039650

Group type: EXPERIMENTAL
Intervention: 400 IU vitamin E and/or 20 μg selenium daily
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 170
Study: 36184602

Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine (AL) chemoprophylaxis with an initial 3 day full treatment course followed by twice daily dosing once a week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Full 3 day AL treatment course given twice a month.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Twice daily treatment given once a week.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Initial 3 day full AL treatment course followed by twice daily dosing once a week.
Number of subjects: 0
Study: 33020040

Group type: EXPERIMENTAL
Intervention: Navigation Grid (NG)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No Navigation Grid (Control)
Number of subjects: 58
Study: 37318667

Group type: EXPERIMENTAL
Intervention: 650 nm low-level red light (LLRL) irradiation for 6 min daily
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 112
Study: 32964729

Group type: EXPERIMENTAL
Intervention: DemTect
Number of subjects: 200
Study: 34716791

Group type: EXPERIMENTAL
Intervention: High polyphenol olive oil (HPOO) 60 mL/day (320 mg/kg polyphenols)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Low polyphenol olive oil (LPOO) 60 mL/day (86 mg/kg polyphenols)
Number of subjects: 50
Study: 32951050

Group type: EXPERIMENTAL
Intervention: AlzRiskMR database
Number of subjects: 1870

Group type: EXPERIMENTAL
Intervention: Two-sample Mendelian randomization (2SMR) analysis methods
Number of subjects: 1870
Study: 32660609

Group type: EXPERIMENTAL
Intervention: pyrotinib + trastuzumab + AI
Number of subjects: 198

Group type: COMPARATOR
Intervention: trastuzumab + AI
Number of subjects: 198
Study: 35107389

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided repetitive thoracic paravertebral block (TPVB) every 48 hours for a week after antiviral therapy
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard antiviral therapy
Number of subjects: 96
Study: 35171143

Group type: EXPERIMENTAL
Intervention: Corvis ST (Scheimpflug tonometer)
Number of subjects: 315
Study: 33514891

Group type: EXPERIMENTAL
Intervention: UNR844 (1.5%) ophthalmic solution, administered unilaterally twice a day for 7 days, then bilaterally twice a day for 91 days
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo, administered unilaterally twice a day for 7 days, then bilaterally twice a day for 91 days
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: UNR844 (1.5%) ophthalmic solution
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 35833956

Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 25389

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25389
Study: 34124261

Group type: EXPERIMENTAL
Intervention: 3D navigational template for Salter osteotomy
Number of subjects: 32

Group type: COMPARATOR
Intervention: Conventional surgical method
Number of subjects: 32
Study: 32068424

Group type: EXPERIMENTAL
Intervention: CBM_RNT (interpretation training condition with prior activation of RNT)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: CBM_ENH (training condition augmented with positive outcome generation and imagery)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Active control condition
Number of subjects: 161
Study: 36477733

Group type: EXPERIMENTAL
Intervention: pioglitazone 30 mg once daily
Number of subjects: 525

Group type: EXPERIMENTAL
Intervention: sitagliptin 100 mg once daily
Number of subjects: 525
Study: 34714720

Group type: EXPERIMENTAL
Intervention: Quadrivalent high-dose inactivated influenza vaccine (IIV4-HD)
Number of subjects: 1528

Group type: COMPARATOR
Intervention: Standard-dose quadrivalent influenza vaccine (IIV4-SD)
Number of subjects: 1528

Group type: EXPERIMENTAL
Intervention: Both vaccines (IIV4-HD and IIV4-SD)
Number of subjects: 1528
Study: 32095884

Group type: EXPERIMENTAL
Intervention: Mill Suss™-guided method (Group M: n=36)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Ultrasound-guided method (Group U: n=36)
Number of subjects: 72
Study: 34209476

Group type: EXPERIMENTAL
Intervention: Traditional stoves
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Cooking duration
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: WHO guideline limit
Number of subjects: 150
Study: 32696396

Group type: EXPERIMENTAL
Intervention: Leflunomide
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard supportive treatment
Number of subjects: 10
Study: 33741010

Group type: EXPERIMENTAL
Intervention: Thrombomodulin
Number of subjects: 3694
Study: 33754528

Group type: EXPERIMENTAL
Intervention: 6-cm quilting
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 3-cm quilting
Number of subjects: 34

Group type: COMPARATOR
Intervention: non-quilting
Number of subjects: 34
Study: 35699175

Group type: EXPERIMENTAL
Intervention: Genotype-guided selection of antiplatelet therapy after PCI
Number of subjects: 5276

Group type: COMPARATOR
Intervention: Conventional therapy with clopidogrel
Number of subjects: 5276
Study: 33450486

Group type: EXPERIMENTAL
Intervention: Intermittent low-dose esomeprazole (40 mg once a day for 8 weeks)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Continuous high-dose esomeprazole (40 mg once a day for 8 weeks)
Number of subjects: 414

Group type: EXPERIMENTAL
Intervention: Intermittent low-dose esomeprazole
Number of subjects: 414

Group type: COMPARATOR
Intervention: Continuous high-dose esomeprazole
Number of subjects: 414
Study: 33882292

Group type: EXPERIMENTAL
Intervention: Expedited discharge (postoperative hospitalization duration of 0 or 1 day)
Number of subjects: 84152

Group type: COMPARATOR
Intervention: Routine discharge (postoperative hospitalization longer than 1 day)
Number of subjects: 84152
Study: 34377044

Group type: EXPERIMENTAL
Intervention: TDT 064 (topical agent)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (identical in appearance)
Number of subjects: 64
Study: 32674230

Group type: EXPERIMENTAL
Intervention: Total Protein Enteral Nutrition (TPEN)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Short Peptide Enteral Nutrition (SPEN)
Number of subjects: 120
Study: 34321051

Group type: EXPERIMENTAL
Intervention: Short-term mentalisation-based therapy (20 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term mentalisation-based therapy (14 months)
Number of subjects: 0
Study: 36110081

Group type: EXPERIMENTAL
Intervention: Caries group (patients with caries)
Number of subjects: 43
Study: 32847643

Group type: EXPERIMENTAL
Intervention: PRIDE intervention (three-session intervention)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Qualitative feedback from dyads and facilitators
Number of subjects: 34
Study: 32325162

Group type: EXPERIMENTAL
Intervention: Individualized Comprehensive Rehabilitation Program (ICRP) for 8 weeks
Number of subjects: 38

Group type: COMPARATOR
Intervention: Leaflet with ergonomic information (Control)
Number of subjects: 38
Study: 35842329

Group type: EXPERIMENTAL
Intervention: Volar locking plate
Number of subjects: 150

Group type: COMPARATOR
Intervention: Combined plating
Number of subjects: 150
Study: 32495059

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injection (bevacizumab or ranibizumab)
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injection (bevacizumab) in HTG
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: Intravitreal anti-VEGF injection (ranibizumab) in NTG
Number of subjects: 550
Study: 36362815

Group type: EXPERIMENTAL
Intervention: 300 mg of colon-targeted microencapsulated sodium butyrate combined with probiotic Lactobacillus strains (L. rhamnosus and L. acidophilus) and Bifidobacterium strains (B. longum, B. bifidum, B. lactis), and 64 mg of prebiotic scFOS
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 34810350

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouth rinse
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: 0.5% green tea extract mouth rinse
Number of subjects: 50
Study: 34244224

Group type: EXPERIMENTAL
Intervention: Routine Diet (RD)
Number of subjects: 214

Group type: COMPARATOR
Intervention: Low-Carbohydrate, High-Fat Diet (LCHFD)
Number of subjects: 214
Study: 32127584

Group type: EXPERIMENTAL
Intervention: Single-use MR contrast injector (SI)
Number of subjects: 365

Group type: COMPARATOR
Intervention: Multi-use MR contrast injector (MI)
Number of subjects: 365
Study: 34809581

Group type: EXPERIMENTAL
Intervention: VieScope
Number of subjects: 35

Group type: COMPARATOR
Intervention: GlideScope (Control)
Number of subjects: 35
Study: 33085237

Group type: EXPERIMENTAL
Intervention: SRP with a periodontal endoscope
Number of subjects: 0

Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 0
Study: 34466041

Group type: EXPERIMENTAL
Intervention: Positive deviance approach (PDA) intervention with counseling and social support to promote EBF
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual community-based services from urban health extension professionals (Control)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Positive deviance approach (PDA) intervention
Number of subjects: 260
Study: 33040012

Group type: EXPERIMENTAL
Intervention: Health-RESPECT intervention involving comprehensive geriatric assessment, individualised care plan, medication and rehabilitation management, periodic video-conference, and in-system assessment.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract).
Number of subjects: 0
Study: 36216679

Group type: EXPERIMENTAL
Intervention: BNT162b2 vaccine (two doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BNT162b2 booster dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adolescents (after school reopening)
Number of subjects: 0
Study: 33940582

Group type: EXPERIMENTAL
Intervention: Swedish version of the ENDOCARE questionnaire (ECQ)
Number of subjects: 187
Study: 32910638

Group type: EXPERIMENTAL
Intervention: Analysis of papillae geometry and adhesive performance using an image processing tool.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mathematical modeling of surface structures.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Investigation of surface area changes of papillae with fish size.
Number of subjects: 0
Study: 35351147

Group type: EXPERIMENTAL
Intervention: We Care Solar Suitcase intervention (solar electric system providing lighting and power)
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: We Care Solar Suitcase intervention
Number of subjects: 85
Study: 33998206

Group type: EXPERIMENTAL
Intervention: Intravenous administration of TXA (15 mg/kg) 30 minutes before operation (Group A)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Topical administration of TXA (1 g injected into the medullary cavity after proximal femur grooving) (Group B)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Combined administration of TXA (Groups A and B methods) (Group C)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but can be inferred as no TXA administration)
Number of subjects: 107
Study: 34560833

Group type: EXPERIMENTAL
Intervention: Warm-water footbath
Number of subjects: 68

Group type: COMPARATOR
Intervention: Control
Number of subjects: 68
Study: 35570728

Group type: EXPERIMENTAL
Intervention: Remote supervised group (RSG)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Unsupervised group (UG)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 66
Study: 34021585

Group type: EXPERIMENTAL
Intervention: Rimegepant
Number of subjects: 257
Study: 32891212

Group type: EXPERIMENTAL
Intervention: Vosoritide 15.0 μg/kg
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 33484513

Group type: EXPERIMENTAL
Intervention: Mesh fixation (Group A)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Non-mesh fixation (Group B)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study: 32493199

Group type: EXPERIMENTAL
Intervention: Non-invasive ventilation (NIV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-flow nasal cannulae
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional invasive ventilation
Number of subjects: 0
Study: 35500205

Group type: EXPERIMENTAL
Intervention: Audio-written instructions
Number of subjects: 82

Group type: COMPARATOR
Intervention: Written-only instructions
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study: 34298539

Group type: EXPERIMENTAL
Intervention: SDL-Seg algorithm
Number of subjects: 29

Group type: COMPARATOR
Intervention: basic U-Net
Number of subjects: 29
Study: 32293478

Group type: EXPERIMENTAL
Intervention: Antipyretic
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Abortive (corticosteroids)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prophylaxis (colchicine or cimetidine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical (tonsillectomy)
Number of subjects: 0
Study: 34844978

Group type: EXPERIMENTAL
Intervention: Fulvestrant plus Everolimus
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Fulvestrant, Everolimus, and Anastrozole
Number of subjects: 37

Group type: COMPARATOR
Intervention: Fulvestrant alone
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Baseline CTC and ctDNA
Number of subjects: 37
Study: 33974019

Group type: EXPERIMENTAL
Intervention: Digital intervention (18-session, low-intensity, delivered over 6 weeks via smartphone)
Number of subjects: 1312

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 1312
Study: 33338989

Group type: EXPERIMENTAL
Intervention: Moderate stress
Number of subjects: 62

Group type: COMPARATOR
Intervention: Low/no stress, mental stress, physical stress
Number of subjects: 62
Study: 35554859

Group type: EXPERIMENTAL
Intervention: Evening binge alcohol consumption (1 g/kg in men, 0.85 g/kg in women)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Fluid control
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Evening binge alcohol consumption
Number of subjects: 30
Study: 34039635

Group type: EXPERIMENTAL
Intervention: Spectral endoscopy
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Deep learning algorithm for spectral classification
Number of subjects: 20

Group type: COMPARATOR
Intervention: Application-specific color filters
Number of subjects: 20
Study: 35272319

Group type: EXPERIMENTAL
Intervention: Urgent PC
Number of subjects: 501

Group type: COMPARATOR
Intervention: Generic posterior tibial neurostimulator
Number of subjects: 501